Theratechnologies Resumes Distribution of Egrifta in the US

Theratechnologies Inc. has announced that a first shipment of Egrifta (tesamorelin for injection) was sent to its US-based wholesale distributor to replenish the supply chain. As a consequence, Egrifta will once again be available to patients in the US by mid-September, as planned.

New batches of the 1-mg presentation of Egrifta have been manufactured since June. Production of additional batches is already scheduled and will occur over the next weeks and months.

“I am extremely pleased that Egrifta will soon be available again to patients who need this treatment. This is also welcome news for shareholders as resumption of commercial activities will have a direct, immediate and positive impact on the financials of our company” said Luc Tanguay, President and CEO, Theratechnologies Inc. 

This represents the first commercial activity for Theratechnologies in the US since regaining rights to Egrifta in this territory in May 2014.

“This is an important milestone for the company as we recently regained all rights to Egrifta in the US. We are now in a position to fully benefit from this transaction. By assuming marketing and sales responsibilities, Theratechnologies is now poised to make significant headway in the US,” added Mr Tanguay.

Shipment of Egrifta to the US had to be interrupted last April due to difficulties experienced with the manufacturing process of the 2-mg presentation. After consulting with regulatory authorities, it was decided to revert to the original 1mg presentation, which was first approved by FDA November 2010 and did not experience any commercial delay with the manufacturing of the 1-mg presentation.